Patent intelligence · US
US 12152038
Vasopressin receptor antagonists and products and methods related thereto
Vasopressin receptor antagonists and products and methods related thereto
Patent details — US 12152038
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 26, 2024
- Expiration
- Nov 21, 2044
- Applicant
- Neumora Therapeutics, Inc.
- Claims
- 123
- CPC classes
- A61P, A61P25/00, A61P25/18, A61P25/20
Quick answer
US 12152038 (Vasopressin receptor antagonists and products and methods related thereto) is held by Neumora Therapeutics, Inc.. Status: granted. Granted Nov 26, 2024. Expires Nov 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Neumora Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 123
- CPC classes
- A61P, A61P25/00, A61P25/18, A61P25/20, A61P25/22, A61P25/24
More from Neumora Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12371414
Methods of treating neurological disorders
granted -
US 12247037
1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders
granted -
US 12171758
Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto
granted -
US 11993580
Methods of treating neurological disorders
granted -
US 11858943
Vasopressin receptor antagonists and products and methods related thereto
granted
Frequently asked questions
What is US patent 12152038?
US 12152038 (Vasopressin receptor antagonists and products and methods related thereto) is held by Neumora Therapeutics, Inc.. Status: granted. Granted Nov 26, 2024. Expires Nov 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12152038?
Neumora Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 12152038 expire?
Our index shows an expiration date of Nov 21, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.